NYSE · Healthcare
InfuSystem Holdings, Inc (INFU)
As-reported financials and recent SEC filings for InfuSystem Holdings, Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$143.4M
Net income
$6.6M
Net margin
4.6%
Diluted EPS
$0.31
ROE
11.6%
P/E (TTM)
—
Market cap
—
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $143.4M | $134.9M | $125.8M | $109.9M | $102.4M |
| Gross profit | $80.3M | $70.4M | $63.1M | $60.6M | $58.5M |
| Operating income | $11.9M | $6.9M | $4.1M | $1.7M | $2.8M |
| Net income | $6.6M | $2.3M | $872,000 | $18,000 | $1.4M |
| Diluted EPS | $0.31 | $0.11 | $0.04 | $0.00 | $0.06 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →8-K2026-05-18
View on EDGAR →S-82026-05-18
View on EDGAR →42026-05-14
View on EDGAR →42026-05-14
View on EDGAR →Largest Healthcare peers
Go deeper on INFU
Search InfuSystem Holdings, Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.